

# Notice of Allowability

Application No.

10/630,901

Examiner

Vickie Kim

Applicant(s)

RAMAN ET AL.

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to examiner's amendment requested on 4/2/05.
2. ☒ The allowed claim(s) is/are 1-13.
3. ☐ The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☒ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☒ Certified copies of the priority documents have been received in Application No. 10/051,173.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
  - \* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

## Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date 3/04 & 7/03
4. ☐ Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),  
Paper No./Mail Date 4/2/05.
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_

Vickie Kim  
Primary Patent Examiner

### EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Mitchard, Leonard C. on April 02, 2005.

2. The application has been amended as follows:

a. In claim 1, lines 1-2, delete [ a subject having a skin condition selected from the group of conditions (a) those treatable by stimulation of melanocyte proliferation] and replace with --- a skin condition of a subject wherein the skin condition is selected from the group of conditions (a) vitiligo --- right between "treating " and "and".

b. In claim 2, lines 1-2, delete [the subject is a patient suffering from] and replace with --- the skin condition is a melanoma and the subject is a patient--

c. In claim 3, lines 1-2, delete [the subject is a patient suffering from a skin disorder" and replace with -- the subject is a patient and the skin condition is -- right before "treatable".

d. In claim 4, delete [skin disorder} and replace with -- skin condition --- right after "wherein".

e. In claim 10, lines 1-3, delete [ a subject having a skin condition selected from the group of conditions (a) those treatable by stimulation of melanocyte

Art Unit: 1614

proliferation] and replace with --- a skin condition of a subject wherein the skin condition is selected from the group of conditions (a) vitiligo --- right between "treating " and "and".

f. In claim 11, lines 1-2, delete [the subject is a patient suffering from] and replace with --- the skin condition is a melanoma and the subject is a patient--

g. In claim 12, lines 1-2, delete [the subject is a patient suffering from a skin disorder" and replace with -- the subject is a patient and the skin condition is -- right before "treatable".

h. In claim 13, delete [skin disorder} and replace with -- skin condition --- right after "wherein".

***Reason for allowance***

3. The following is an examiner's statement of reasons for allowance: Banerji et al(1973) teaches a sylvatine, new alkaid from piper sylvaticum. However, it fails to teach the generic sturucture with piperidine ring and its use in the treatment of vitiligo and melanoma. As mentioned in the parent case, the compound having specific structure of formula (I) is allowable and the method of treating skin conditions(i.e. vitiligo and melanoma) using the said compound as claimed has not taught in the prior art of the record and considered to be novel.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Art Unit: 1614

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Conclusion**

1. All pending claims 1-13 are allowed.
2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Chris Low be reached on 571-272-0953. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**VICKIE KIM**  
**PRIMARY EXAMINER**

Vickie Kim  
April 4, 2005  
Art unit 1614